Comparative Analyses of the Symbiotic Associations of the Host Paramecium bursaria with Free-Living and Native Symbiotic Species of Chlorella.

Each symbiotic Chlorella variabilis associated with the ciliate Paramecium bursaria is enclosed in a symbiosome called the perialgal vacuole. Various potential symbionts, such as bacteria, yeasts, other algae, and free-living Chlorella spp., can infect P.

Genetic and phenotypic analysis of 101 patients with developmental delay or intellectual disability using whole-exome sequencing.

Whole-exome sequencing (WES) enables identification of pathogenic variants, including copy number variants (CNVs). In this study, we performed WES in 101 Japanese patients with unexplained developmental delay (DD) or intellectual disability (ID) (63 males and 38 females), 98 of them with trio-WES. Pathogenic variants were identified in 54 cases (53.

Mothers' experiences of parenting a child with chromosomal structural abnormalities: The journey to acceptance.

Purpose: This study aimed to investigate the process mothers go through in coming to terms with raising a child with chromosomal structural abnormalities.

Methods: Sixteen mothers living in Japan were interviewed and a modified grounded theory approach was used for the analysis.

Results: A total of 35 concepts, nine subcategories, and six categories were extracted.

Curcumin inhibits adipogenesis induced by benzyl butyl phthalate in 3T3-L1 cells.

Phthalates are a group of endocrine disrupting chemicals and may have contributed to the recent global obesity health crisis. Increased adipogenesis via the peroxisome proliferator-activated receptor γ (PPARγ)-CCAAT-enhancer binding protein α (C/EBPα) pathway could be one critical mechanism responsible for phthalate-induced weight gain. On the other hand, curcumin has been shown to inhibit adipogenesis in cells and animal models.

Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.

Aims: To elucidate the effects of intensive LDL-C lowering treatment with a standard dose of statin and ezetimibe in patients with dyslipidaemia and high risk of coronary events, targeting LDL-C less than 70 mg/dL (1.8 mmol/L), compared with standard LDL-C lowering lipid monotherapy targeting less than 100 mg/dL (2.6 mmol/L).